Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia

Journal of Pharmacological Sciences
Sutep JaruratanasirikulMaseetoh Samaeng

Abstract

The aims of this study were to i) reveal the population pharmacokinetics; and ii) assess the probability of target attainment (PTA) and cumulative fraction of response (CFR) (defined as the expected population PTA for a specific drug dose and a specific population of microorganisms) of imipenem in febrile neutropenic patients with bacteraemia. Ten patients were randomised into two groups: Group I received a 0.5-h infusion of 0.5 g of imipenem every 6 h (q6h) for 8 doses; and Group II received a 4-h infusion of 0.5 g q6h for 8 doses. A Monte Carlo simulation was performed to determine the PTA. The volume of distribution and total clearance of imipenem were 20.78 ± 1.35 l and 23.19 ± 1.34 l/h, respectively. Only a 4-h infusion of 1 g q6h regimen achieved a PTA >93% for 80% T>MIC for a MIC of 2 μg/ml. A 4-h infusion of all simulated regimens and a 0.5-h infusion of 0.5 g q6h and 1 g q6h achieved targets (CFR ≥ 90%) against Escherichia coli and Klebsiella spp. However, against Pseudomonas aeruginosa and Acinetobacter spp., no regimens achieved their targets. In conclusion, the results indicate that a higher than manufacturer's dosage recommendation is required to maximize the activity of imipenem.

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Oct 1, 1988·The Journal of Infectious Diseases·B VogelmanW A Craig
Sep 1, 1987·Antimicrobial Agents and Chemotherapy·G L DrusanoJ C Wade
Apr 25, 1997·Journal of Chromatography. B, Biomedical Sciences and Applications·L Garcia-CapdevilaJ Bonal
May 25, 2002·Drug Development and Industrial Pharmacy·Nimit WorakulPrapaporn Boonme
Jan 8, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G L Drusano
May 3, 2003·International Journal of Antimicrobial Agents·Jean A Klastersky
Mar 16, 2004·Fundamental & Clinical Pharmacology·Eric DaillyMichel Bourin
Oct 20, 2005·The Journal of Antimicrobial Chemotherapy·Sutep JaruratanasirikulSomchai Sriwiriyajan
Dec 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael S Niederman
Sep 26, 2006·The Journal of Antimicrobial Chemotherapy·A C RodloffA Torres
Sep 11, 2007·Journal of Pharmacological Sciences·Akihiro TanakaHiroaki Araki
Oct 17, 2008·The Lancet Infectious Diseases·Olivier LortholaryUNKNOWN Club de Reflexion sur les Infections en Onco-Hématologie
Jul 3, 2010·Critical Care : the Official Journal of the Critical Care Forum·Fabio Silvio TacconeFrédérique Jacobs
Dec 2, 2010·The Journal of Antimicrobial Chemotherapy·Jason A RobertsJeffrey Lipman

❮ Previous
Next ❯

Citations

May 6, 2016·The Journal of Antimicrobial Chemotherapy·Pieter ColinAn Vermeulen
Aug 2, 2020·The Journal of Antimicrobial Chemotherapy·A ContejeanD Hirt
Aug 2, 2019·International Journal of Antimicrobial Agents·Marissa D MalchioneJesse L Goodman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

© 2022 Meta ULC. All rights reserved